Prelude Therapeutics Inc - PRLD

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Jul 08, 2026 SCHEDULE 13G Soleus Private Equity Fund III, L.P. 1.0% 675,676 View
Jul 08, 2026 SCHEDULE 13G Soleus Private Equity GP III, LLC 1.0% 675,676 View
Jul 08, 2026 SCHEDULE 13G Soleus PE GP III, LLC 1.0% 675,676 View
Jul 08, 2026 SCHEDULE 13G Soleus Capital Master Fund, L.P. 4.2% 2,702,702 View
Jul 08, 2026 SCHEDULE 13G Soleus Capital, LLC 4.2% 2,702,702 View
Jul 08, 2026 SCHEDULE 13G Soleus Capital Group, LLC 4.2% 2,702,702 View
Jul 08, 2026 SCHEDULE 13G Soleus Capital Management, L.P. 5.2% 3,378,378 View
Jul 08, 2026 SCHEDULE 13G Soleus GP, LLC 5.2% 3,378,378 View
Jul 08, 2026 SCHEDULE 13G Levy Guy 5.2% 3,378,378 View
Apr 28, 2026 SCHEDULE 13G RA Capital Management, L.P. 9.9% 6,477,309 View
Apr 28, 2026 SCHEDULE 13G Peter Kolchinsky 9.9% 6,477,309 View
Apr 28, 2026 SCHEDULE 13G Rajeev Shah 9.9% 6,477,309 View
Apr 28, 2026 SCHEDULE 13G RA Capital Healthcare Fund, L.P. 9.9% 6,477,309 View
Apr 23, 2026 SCHEDULE 13D/A — 1.0% — View
Apr 22, 2026 SCHEDULE 13D/A — 9.99% — View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.